Literature DB >> 24575779

Phenazopyridine associated acute interstitial nephritis and review of literature.

Manisha Singh1, Fnu Shailesh, Upasana Tiwari, Shree G Sharma, Bilal Malik.   

Abstract

Phenazopyridine is a urinary analgesic; commonly seen side-effects of this drug include, orange discoloration of urine, methemoglobinemia, yellowish skin discoloration, hepatitis and acute renal failure. Various case reports with phenazopyridine associated acute renal failure secondary to acute tubular necrosis have been reported in the literature. Acute kidney injury in these patients is caused by either direct injury to renal tubular epithelial cells or secondary to pigment induced nephropathy from hemolytic anemia. Hypoxic injury from phenazopyridine-induced methemoglobinemia has been well documented. We report a case of biopsy proven acute interstitial nephritis, associated with therapeutic doses of phenazopyridine without any evidence of methemoglobinemia or other mechanism of renal injury. Clinicians should be aware of the toxicity of this commonly used drug and should look closely for signs of renal insufficiency. Identifying and stopping the offending medication stays as the first step, but recent studies indicate that early steroid administration improves renal recovery, as well as decreasing the risk of progression to chronic kidney disease with fibrosis and consequent permanent renal damage.

Entities:  

Keywords:  Acute kidney injury; acute interstitial nephritis; creatinine; phenazopyridine; renal biopsy

Mesh:

Substances:

Year:  2014        PMID: 24575779     DOI: 10.3109/0886022X.2014.890054

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

1.  Managing Interstitial Cystitis/Bladder Pain Syndrome in Older Adults.

Authors:  Alyssa Gracely; Anne P Cameron
Journal:  Drugs Aging       Date:  2020-10-23       Impact factor: 3.923

2.  Sabulous cystitis in the horse: 13 cases (2013-2020).

Authors:  Luiza S Zakia; Diego E Gomez; Daniel G Kenney; Luis G Arroyo
Journal:  Can Vet J       Date:  2021-07       Impact factor: 1.008

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.